Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor.
about
Pleiotropic effects of statinsStatins as regulators of redox state in the vascular endothelium: beyond lipid loweringStatins in heart failure: do we need another trial?Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblastsStatins Decrease Oxidative Stress and ICD Therapies.Statins and cardiovascular diseases: from cholesterol lowering to pleiotropyBcl10 mediates angiotensin II-induced cardiac damage and electrical remodeling.Cardiac protection by pharmacological modulation of inflammation.Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysmsRelaxin does not improve Angiotensin II-induced target-organ damage.A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanismsSimvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathwayStatins and myocardial hypertrophy.Statin therapy for cardiac hypertrophy and heart failureRosuvastatin reduces neointima formation in a rat model of balloon injury.Statins and the myocardiumPotential autonomic nervous system effects of statins in heart failure.Atorvastatin and statins in the treatment of heart failure.Spectrum of pleiotropic effects of statins in heart failure.Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review.Established and emerging approaches for the management of dyslipidaemia.Potential novel pharmacological therapies for myocardial remodelling.Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.Statin therapy--Part II: Clinical considerations for cardiovascular disease.From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation.The antihypertensive actions of statins: modulation by salt intake.Most appropriate animal models to study the efficacy of statins: a systematic review.Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure.High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin.Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptorStatin-induced impairment of monocyte migration is gender-related.Heat shock treatment protects against angiotensin II-induced hypertension and inflammation in aorta.Effect of simvastatin on collagen I deposition in non-infarcted myocardium: role of NF-κB and osteopontin.Statins and modulation of oxidative stress.Effect of targeting mitogen-activated protein kinase on cardiac remodeling in rats.Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure.Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive patients.Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial.Heat shock treatment suppresses angiotensin II-induced activation of NF-kappaB pathway and heart inflammation: a role for IKK depletion by heat shock?
P2860
Q24647863-1AD2F794-AA45-489D-B73F-EF30141E717FQ26853120-FB0E6F8F-F1E6-445A-87A1-D307931B12B6Q26998966-975ACE33-F9C1-4062-9C2C-AA043FFCD92EQ28568492-111CEE81-F865-48A0-8172-902209BCB01CQ33760881-F059E6BF-4548-43AD-9699-1105874FF4C4Q33960556-06D45CFD-FF34-4104-B953-B20B41D8AAFDQ34315544-31349D70-57A7-409D-A8C6-B7F60A61BBF4Q34481804-EBA590F5-3510-40A4-B676-DDB9B34F8ADEQ35048624-B7D81C0C-6C42-47E5-9832-6D3E0DF58CD0Q35141812-D10750A3-2A1F-4601-8E00-1833D3F9349FQ35565491-E7AD9FCD-C662-470D-B1AA-43727E57CD8DQ35794521-5E4E1249-6F1D-4028-AA9F-285776CF9794Q35828423-AF626C8D-F98F-47D2-933D-61B334270BBCQ35936804-FE8BDE5F-5E58-49EA-B3F7-4EC4D4D90C84Q35961612-40FF3031-A946-4C3D-88BA-2854E446273FQ36110624-05793D36-96A2-4F59-8F9E-FF6B3128CF3BQ36736899-62D12DC8-D688-4B2D-8BA7-F4EA206E6649Q37000767-B644EB0C-E116-468A-8A5D-9CD90748AE5BQ37146694-E9FF80BA-D708-455F-8C6E-6ABC01119637Q37284133-1601FBB6-BAFF-4E49-B115-1D030415AF17Q37288105-4F371DBC-EFB3-40DC-AD88-C09E706D5568Q37329709-D8A991B9-8720-4139-9D1D-26E7E476DA90Q37734257-4D569456-0A71-4834-AA3D-ADDF92785809Q37765064-EC95AA91-889B-46BF-B0D0-86657358F9ACQ37786549-1B8F11E4-B227-455F-977F-1F80A946970AQ38029526-C6A0C4AF-0775-4A08-9535-7457F1D81C0FQ38234426-F916C8B9-7E84-437C-8900-F35246AF169EQ39401767-63FC1781-F070-40A9-97F8-3688A69A355BQ41807679-61852105-81A0-4C59-A2B2-E8DA76918EF5Q42169686-5E22DDA1-289F-4484-92CF-7FBD9C06762DQ42217471-F9BF92E4-8840-4F3C-9735-B63055EB8504Q42228570-1AFF2C5F-82B9-4533-A05D-8A14E23ED625Q42816496-77483FFE-813B-4A8A-95B0-92E137604CD0Q43215640-2BD62B7D-5D1D-4423-8615-B2FE3B2A7C6EQ43244751-FF87AE6E-2DF5-4BFB-8E7D-342332122D62Q45011976-17CB8B3F-178D-4B6C-964B-07B22D7D147CQ45071766-D35ED448-C7F6-4B35-9813-CBE88E1F768CQ45934157-E706B6A2-20CC-4CE6-B9B6-4B8B17FDB9C1Q47755897-45173BB2-A3ED-4A30-A123-FB3222974E92
P2860
Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Amelioration of angiotensin II ...... oenzyme a reductase inhibitor.
@en
type
label
Amelioration of angiotensin II ...... oenzyme a reductase inhibitor.
@en
prefLabel
Amelioration of angiotensin II ...... oenzyme a reductase inhibitor.
@en
P2093
P356
P1433
P1476
Amelioration of angiotensin II ...... oenzyme a reductase inhibitor.
@en
P2093
Bieringer M
Fiebeler A
Mervaala E
P304
P356
10.1161/HC3001.092039
P407
P577
2001-07-01T00:00:00Z